Handbook of Animal Models and its Uses in Cancer Research

ISBN-13: 9789811938238 / Angielski / Twarda / 2023 / 1196 str.

Surajit Pathak; Antara Banerjee; Atil Bisgin

Opis

This reference book compiles together different animal models in cancer research. It provides knowledge and a better understanding of the advancement of the molecular and cellular mechanisms associated with the progression, formation, and clinical results of various types of cancer from the evidence collected from animal models utilized for cancer research. It discusses animal models for screening anti-cancer drugs and exploration of gene therapy. It presents different methods used to construct cancer animal models and the progress of each animal model in tumor research. The book also highlights the applications of genetic engineering, including CRISP/Cas9, in designing and developing animal models for cancer research. Further, it discusses strategies for modeling animals for investigating growth, metastasis, tumor-associated inflammation and microenvironment, cancer stem cells, tumor heterogeneity, and therapeutic resistance. This book is s a valuable resource for basic and translational cancer researchers, clinicians, and health care.

Spis treści

Chapter 1_Importance of animal models in the field of cancer research. -Chapter 2_Cancer study: cell to the animal models. -Chapter 3_Animal models for cancer research: the choice of the right model system. -Chapter 4_Mouse as a model for different types of cancer. -Chapter 5_Zebrafish as an animal model for cancer research. -Chapter 6_Animal models for angiogenesis on cancer research. -Chapter 7_Orthotopic PDX and CDX mice model for cancer stem cell research. -Chapter 8_Chemical-induced hepatocellular carcinoma in Animal Model. -Chapter 9_Animal model of Breast Cancer. -Chapter 10_The use of mouse to model human colorectal cancer. -Chapter 11_Translatability of experimental animal cancer models for clinical development of biomarkers. -Chapter 2_Available preclinical tools for Neuroblastoma. -Chapter 13_Animal model of human cancer: Malignant lymphoma/ Colon Cancer/ lung Cancer/ Liver Cancer/ Brain Tumors/Skin cancer. -Chapter 14_Tumor models of Retinoblastoma: in vivo, ex vivo and in vitro models. -Chapter 15_Animal models for bone metastasis study. -Chapter 16_Animal model of Inflammatory Bowel Disease leading to cancer and Role of Genetic variation in colitis associated cancer. -Chapter 17_Animal Models in Women Cancer Research. -Chapter 18_Chorioallantoic membrane (CAM) and in ova models as potential platforms for testing cancer agents. -Chapter 19_Triple-negative breast cancer (tnbc) - clinical features and therapeutic targets. -Chapter 20_Role of Melatonin in Zebrafish Cancer Model. -Chapter 21_Stem Cell-derived Exosomes a promising therapeutic role in colorectal cancer. -Chapter 22_Optical Techniques for Treatment and Tissue Evaluation using Skin models for pre-clinical studies. -Chapter 23_Endocrine Regulation of Cancer in Zebra Fish Model. -Chapter 24_A study on the role of phytochemicals in the preclinical neuronal cancer. -Chapter 25_Prespectives of stem cell therapy: A promising therapeutic for cancer model and Alzheimers disease. -Chapter 26_Engineering exosomes for cancer theranostic applications using animal model. -Chapter 27_Use of Stem Cells on Animal Model of Cancer Research. -Chapter 28_Limitation and Advantages of MicroRNA Research in Colorectal Cancer Animal Model. -Chapter 29_Role of Telomere and Telomerase Activator (TA-65) in ageing and cancer. -Chapter 30_Analyzing the therapeutic efficacy and toxicity of chemicals and biological using animal models. -Chapter 31_Understanding the crosstalk between the experimental animal model and RNA interference: as a novel approach for cancer research. -Chapter 32_Genetics of Pancreatic Carcinogenesis: Current Molecular Insights from Animal Models. -Chapter 33_Genetically engineered and spontaneous animal model: utilization in preclinical cancer therapy development. -Chapter 34_Engineering and studying syngeneic animal tumors and Large animal endogenous tumor models. -Chapter 35_Role of animal research to understand the prospects for chemoprevention of cancer. -Chapter 36_Therapeutic molecular targets of cancer and animal models: adequacy and drawbacks. -Chapter 37_Terpenoids as chemopreventive agents and their interpretation in animal models and human clinical trials. -Chapter 38_Dectection of tumors through fluroscein conjugated dye in animal model. -Chapter 39_Biomaterials based drug delivery for cancer treatment: Use of Animal Models. -Chapter 40_Radiopharmaceuticals – A New Era in Cancer Therapy: Light on initial findings on Animal Model. -Chapter 41_Cancer modeling: modern imaging applications in the development of a unique animal model system to analyze cancer advancement and treatment. -Chapter 42_Experimental model for pancreatic cancer and its therapeutic implications in clinical research. -Chapter 43_Association of animal models in the field of cancer translational medicine: Prediction and Validation. -Chapter 44_Bioreactor Based Tissue Models as an Alternative Approach in Cancer Research. -Chapter 45_Repurposing of Drug in cancer research: Utility of Animal Models. -Chapter 46_Precilinical Data translation into clinical model. -Chapter 46_Alternative animal models in cancer research.

​

O autorze

Prof. Surajit Pathak, PhD is currently working as a Professor at Chettinad Academy of Research and Education, Chennai, India (From 2015-till date). He is currently also working in Linkoping University, Linkoping, Sweden as a Principal Research Scientist (2022 June- Dec 2022). He has received his Ph.D. degree from India in 2007 and completed his post-doctoral training (2007-2015) from the University of Alabama, USA, University of Padova, Italy and University of Linkoping, Sweden.

His current research focuses on “Biomarker discoveries for early detection of colorectal cancer”. He has published more than 100 research articles in peer-reviewed international journals of repute with 2100 citations and 27 H-index. He received various research grants including Core International and National research grants from SERB-CRG (DST, Govt of India) and DST Indo-Italy Bi-lateral research projects and from other international funding agencies. He has various active International and National Research collaboration.

He is the editorial board member of various renowned international high impact journals. Dr. Pathak has Edited Springer Nature book entitled “Cancer Stem Cells: New Horizon Cancer Therapy” in 2020 and Elsevier Book "Stem Cells and Aging" in 2021. He is the member of various professional research bodies of India including Indian Association of Cancer Research, Indian Science Congress, and Aesthetic Multispecialty Society (AMS). 

Dr. Antara Banerjee is presently working as an Associate Professor at Chettinad Academy of Research and Education (CARE), Chennai. After completing her PhD in 2008 from India, Dr. Banerjee pursued her post-doctoral Later she worked as a Research Associate at Linkoping University, Sweden till 2015. She has published over 90 peer-reviewed research articles in International and National Journals with citation index-1247 and H-index 18. Her core expertise and interest are to investigate aspects the tumor specific niche as a therapeutic target for colon cancer including the epigenetic signals with the goal of identifying novel therapeutic strategies to improve treatment outcome in patients. The Banerjee’s lab at Chettinad Hospital & Research Institute is now focused on understanding the role of mesenchymal stem cells niche in tissue regeneration and exploring signaling pathways in governing stem cell fate. She received various research grants including Early Career research grants from SERB-ECR, Govt of India, and from other pharmaceutical companies She is Editor of Springer Nature book entitled “Cancer Stem Cells: New Horizon Cancer Therapy, 2020” and Elsevier Book "Stem Cells and Aging" in 2021. She is the member of various professional research bodies of India and abroad including Indian Association of Cancer Research, Indian Science Congress.

Dr. Atil Bisgin was born in 1979 and had medical education in Cukurova University, then Medical Genetics in Akdeniz University. In 2015, he established AGENTEM where more than 15000 molecular tests per annum have been performed including NGS-multi-gene panels, clinical exome, whole exome, and whole genome sequencing. He performed more than 400 presentations, 150 as an invited speaker, and has more than 100 published papers in indexed journals. He has on-going international research projects and multi-centric multi-phase clinical trials in oncology and rare diseases. He is a board member of human/medical genetics societies about novel technologies in diagnostics, quality assessments and establishment of national databases for several countries. He has been working in Cukurova University Medical Genetics Department since he established in 2013 within international institutional cooperation. He gives training courses for newly established next-generation-sequencing laboratories and multi-omics research centers, designs (inter) nationwide targeted multigene panels for clinical practice and pipelines, also gives service of genetic testing with clinical reporting via his Infogenom-AB initiative. He is giving lectures in medical faculty and responsible for bioinformatics, immuno-/onco-genetics, translational medicine and biotechnology masters’ degree and PhD training in Institutes of Natural and Applied Sciences, Health Sciences and Addiction and Forensic Sciences.